74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Arvinas Inc
Closed
SectorHealthcare
9.13 0.88
Overview
Share price change
24h
Min
9.01
Max
9.23
Income | 4.1M -45M |
|---|---|
Sales | -43M 59M |
EPS | -0.63 |
Profit margin | -76.182 |
Employees | 430 |
EBITDA | 3.7M -57M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +271.33% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | 602M |
|---|---|
Previous open | 8.25 |
Previous close | 9.13 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Arvinas Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Arvinas Inc Forecast
Price Target
By TipRanks
271.33% upside
12 Months Forecast
Average 33.94 USD 271.33%
High 81 USD
Low 10 USD
Based on 20 Wall Street analysts offering 12 month price targets forArvinas Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
